{
 "genere_le": "2026-10-18T13:34:21.546Z",
 "resolutions": [
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?",
     "source": "SEC : 18 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?",
     "source": "vérificateur en erreur : 100 dépôts trouvés mais aucun de « facebook » — terme de recherche à revoir",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "ia-anthropic-ipo",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?",
     "source": "SEC : 1 dépôt(s) S-1 contenant \"Anthropic\" — le plus récent du 2026-09-03 (Oura Inc.  (CIK 0002133022))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/2133022/000119312526381855/d119865ds1.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?",
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-08",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-08 (Inhibrx Biosciences, Inc.  (INBX)  (CIK 0002007919))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/2007919/000200791926000047/inbrx-106investorovervie.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    }
   ],
   "le": "2026-09-17T19:24:44.648Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?",
     "source": "vérificateur en erreur : 100 dépôts trouvés mais aucun de « facebook / meta-llama » — terme de recherche à revoir",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?",
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    }
   ],
   "le": "2026-09-17T19:29:15.264Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?",
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-17"
    }
   ],
   "le": "2026-09-17T19:32:24.923Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?",
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?",
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus1",
     "note": null,
     "par": "edgar",
     "question": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?",
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?",
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?",
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-18"
    }
   ],
   "le": "2026-09-18T06:30:12.954Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus2",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    }
   ],
   "le": "2026-09-19T06:30:15.935Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "med-nct06118281",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will trial NCT06118281 (Novo Nordisk A/S) be marked \"Completed\" on ClinicalTrials.gov on or before 29 April 2027?",
      "fr": "L'essai NCT06118281 (Novo Nordisk A/S) sera-t-il marqué « Completed » sur ClinicalTrials.gov au plus tard le 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-19"
    }
   ],
   "le": "2026-09-19T17:17:48.183Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-20"
    }
   ],
   "le": "2026-09-20T06:30:15.776Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-21"
    }
   ],
   "le": "2026-09-21T06:30:13.476Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-22"
    }
   ],
   "le": "2026-09-22T06:30:14.740Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-23"
    }
   ],
   "le": "2026-09-23T06:30:17.865Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-24"
    }
   ],
   "le": "2026-09-24T06:30:18.583Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-25"
    }
   ],
   "le": "2026-09-25T06:30:24.215Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus1",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    }
   ],
   "le": "2026-09-26T06:30:15.861Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus1",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-26"
    }
   ],
   "le": "2026-09-26T22:55:43.546Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-27"
    }
   ],
   "le": "2026-09-27T06:30:13.356Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-28"
    }
   ],
   "le": "2026-09-28T06:30:17.917Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-29"
    }
   ],
   "le": "2026-09-29T06:30:16.378Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-gemini4",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus1",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-09-30"
    }
   ],
   "le": "2026-09-30T06:30:14.567Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-01"
    }
   ],
   "le": "2026-10-01T06:30:16.282Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    }
   ],
   "le": "2026-10-02T06:30:20.983Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    }
   ],
   "le": "2026-10-02T14:03:51.729Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-02"
    }
   ],
   "le": "2026-10-02T14:04:28.343Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    }
   ],
   "le": "2026-10-02T14:04:28.692Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-02"
    }
   ],
   "le": "2026-10-02T14:06:00.305Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-03"
    }
   ],
   "le": "2026-10-03T06:30:16.746Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "ia-gemini4",
     "note": "résolu avant l'échéance",
     "par": "flux",
     "question": {
      "en": "Will Google release a model whose name begins with \"Gemini 4\" before 31 March 2027?",
      "fr": "Google publiera-t-elle un modèle dont le nom commence par « Gemini 4 » avant le 31 mars 2027 ?"
     },
     "source": "Publication officielle : « Gemini 4 Argon: our next era of frontier intelligence » — 2026-09-30",
     "statut": "résolu",
     "url": "https://blog.google/innovation-and-ai/models-and-research/gemini-models/gemini-4-argon/",
     "valide": false,
     "verdict": "oui",
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-04"
    }
   ],
   "le": "2026-10-04T06:30:20.062Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 2 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus2",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    }
   ],
   "le": "2026-10-05T06:30:16.907Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "med-vax31-opus1",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte announce that the VAX-31 phase 3 OPUS-1 trial met its non-inferiority criteria before 31 January 2027?",
      "fr": "Vaxcyte annoncera-t-elle que l'essai de phase 3 OPUS-1 du VAX-31 a atteint ses critères de non-infériorité avant le 31 janvier 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-1\" — le plus récent du 2026-09-03 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000164909426000045/a20260831-8xkxpressrelea.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-05"
    }
   ],
   "le": "2026-10-05T21:58:03.294Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 3 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-06"
    }
   ],
   "le": "2026-10-06T06:30:17.970Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus2",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-07"
    }
   ],
   "le": "2026-10-07T06:30:16.879Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 3 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-08"
    }
   ],
   "le": "2026-10-08T06:30:45.746Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus2",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-09"
    }
   ],
   "le": "2026-10-09T06:30:18.435Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-10"
    }
   ],
   "le": "2026-10-10T06:30:20.796Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-11"
    }
   ],
   "le": "2026-10-11T06:30:24.289Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-12"
    }
   ],
   "le": "2026-10-12T06:30:24.415Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-13"
    }
   ],
   "le": "2026-10-13T06:30:23.987Z"
  },
  {
   "entrees": [
    {
     "date_evenement": null,
     "id": "ia-nvidia-ca-t3",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "rd-selinexor-xport-mm-031-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?",
      "fr": "Karyopharm Therapeutics annoncera-t-elle les résultats principaux de l'essai XPORT-MM-031 de selinexor (indication : myélome multiple précédemment traité) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    },
    {
     "date_evenement": null,
     "id": "med-ad109",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?",
      "fr": "La FDA approuvera-t-elle AD109 (Oxnimbi) de Apnimed (indication : traitement des adultes atteints d'apnée obstructive du sommeil) d'ici le 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-14"
    }
   ],
   "le": "2026-10-14T06:30:26.108Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "rd-selinexor-xport-mm-031-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?",
      "fr": "Karyopharm Therapeutics annoncera-t-elle les résultats principaux de l'essai XPORT-MM-031 de selinexor (indication : myélome multiple précédemment traité) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "med-ad109",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?",
      "fr": "La FDA approuvera-t-elle AD109 (Oxnimbi) de Apnimed (indication : traitement des adultes atteints d'apnée obstructive du sommeil) d'ici le 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-chess-820-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Chess Puzzles score score in Epoch AI's benchmark data reach at least 82.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-scicode-705-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SciCode score score in Epoch AI's benchmark data reach at least 70.5 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-simpleqa-830-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SimpleQA Verified score score in Epoch AI's benchmark data reach at least 83.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-15"
    }
   ],
   "le": "2026-10-15T06:30:24.921Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-vax31-opus2",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-intismeran",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "rd-selinexor-xport-mm-031-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?",
      "fr": "Karyopharm Therapeutics annoncera-t-elle les résultats principaux de l'essai XPORT-MM-031 de selinexor (indication : myélome multiple précédemment traité) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "med-ad109",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?",
      "fr": "La FDA approuvera-t-elle AD109 (Oxnimbi) de Apnimed (indication : traitement des adultes atteints d'apnée obstructive du sommeil) d'ici le 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-chess-820-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Chess Puzzles score score in Epoch AI's benchmark data reach at least 82.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-scicode-705-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SciCode score score in Epoch AI's benchmark data reach at least 70.5 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-simpleqa-830-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SimpleQA Verified score score in Epoch AI's benchmark data reach at least 83.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-16"
    }
   ],
   "le": "2026-10-16T06:30:25.940Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "rd-selinexor-xport-mm-031-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?",
      "fr": "Karyopharm Therapeutics annoncera-t-elle les résultats principaux de l'essai XPORT-MM-031 de selinexor (indication : myélome multiple précédemment traité) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-ad109",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?",
      "fr": "La FDA approuvera-t-elle AD109 (Oxnimbi) de Apnimed (indication : traitement des adultes atteints d'apnée obstructive du sommeil) d'ici le 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-chess-820-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Chess Puzzles score score in Epoch AI's benchmark data reach at least 82.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-scicode-705-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SciCode score score in Epoch AI's benchmark data reach at least 70.5 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-simpleqa-830-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SimpleQA Verified score score in Epoch AI's benchmark data reach at least 83.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "med-dibutepinephrine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Aquestive Therapeutics's dibutepinephrine (Anaphylm) for treatment of Type I allergic reactions, including anaphylaxis by March 30, 2027?",
      "fr": "La FDA approuvera-t-elle dibutepinephrine (Anaphylm) de Aquestive Therapeutics (indication : traitement des réactions allergiques de type I, y compris l’anaphylaxie) d'ici le 30 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202611-37",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for November 2026 be at least 3.7 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-17"
    }
   ],
   "le": "2026-10-17T06:30:22.792Z"
  },
  {
   "entrees": [
    {
     "date_evenement": "2026-09-03",
     "id": "ia-nvidia-ca-t3",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Nvidia report quarterly revenue above $112 billion for Q3 of fiscal year 2027?",
      "fr": "Nvidia annoncera-t-elle un chiffre d'affaires trimestriel supérieur à 112 milliards de dollars pour son T3 de l'exercice 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"NVIDIA\" — le plus récent du 2026-09-03 (NVIDIA CORP  (NVDA)  (CIK 0001045810))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1045810/000104581026000078/nvda-20260902.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-siri-gemini",
     "note": null,
     "par": "flux",
     "question": {
      "en": "Will the new Gemini-powered Siri be available in a stable public release of iOS 27 before 31 December 2026?",
      "fr": "Le nouveau Siri propulsé par Gemini sera-t-il disponible dans une version publique stable d'iOS 27 avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-deepseek-r2",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will DeepSeek release a model named R2 or V5 before 31 March 2027?",
      "fr": "DeepSeek publiera-t-elle un modèle nommé R2 ou V5 avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-meta-muse-ouvert",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Meta release the weights of a model in the Muse family before 30 June 2027?",
      "fr": "Meta publiera-t-elle les poids d'un modèle de la famille Muse avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-mistral-gen4",
     "note": null,
     "par": "hf",
     "question": {
      "en": "Will Mistral AI release a flagship open-weights model of a generation above Mistral 3 before 30 June 2027?",
      "fr": "Mistral AI publiera-t-elle un modèle phare à poids ouverts de génération supérieure à Mistral 3 avant le 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-anthropic-ipo",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Anthropic complete its initial public offering before 31 December 2027?",
      "fr": "Anthropic réalisera-t-elle son introduction en bourse avant le 31 décembre 2027 ?"
     },
     "source": "vérificateur en erreur : HTTP 500 {\"message\": \"Internal server error\"}",
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-ivonescimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve ivonescimab in combination with chemotherapy in EGFR-mutated NSCLC after failure of a tyrosine kinase inhibitor?",
      "fr": "La FDA approuvera-t-elle l'ivonescimab en association avec la chimiothérapie dans le CBNPC EGFR-muté après échec d'un inhibiteur de tyrosine kinase ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-deramiocel",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve deramiocel in Duchenne muscular dystrophy before 30 November 2026?",
      "fr": "La FDA approuvera-t-elle le deramiocel dans la dystrophie musculaire de Duchenne avant le 30 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-povetacicept",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to povetacicept in IgA nephropathy before 15 December 2026?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au povetacicept dans la néphropathie à IgA avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-bbp418",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve BBP-418 in limb-girdle muscular dystrophy type 2I/R9 before 15 December 2026?",
      "fr": "La FDA approuvera-t-elle le BBP-418 dans la dystrophie des ceintures de type 2I/R9 avant le 15 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-cagrisema",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve CagriSema for weight management before 31 December 2026?",
      "fr": "La FDA approuvera-t-elle le CagriSema dans la gestion du poids avant le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-relutrigine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies before 15 January 2027?",
      "fr": "La FDA approuvera-t-elle la relutrigine dans les encéphalopathies développementales et épileptiques SCN2A/SCN8A avant le 15 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-zrostudirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA grant accelerated approval to z-rostudirsen in exon 51 skip-amenable DMD before 15 February 2027?",
      "fr": "La FDA accordera-t-elle une approbation accélérée au z-rostudirsen dans la DMD amendable au saut de l'exon 51 avant le 15 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-lonvoz",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lonvoguran ziclumeran in hereditary angioedema before 31 March 2027?",
      "fr": "La FDA approuvera-t-elle le lonvoguran ziclumeran dans l'angio-œdème héréditaire avant le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-tinlarebant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve tinlarebant in Stargardt disease type 1 before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle le tinlarebant dans la maladie de Stargardt de type 1 avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-cefiderocol-ped",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve the paediatric extension of cefiderocol before 30 April 2027?",
      "fr": "La FDA approuvera-t-elle l'extension pédiatrique du céfidérocol avant le 30 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-varegacestat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve varegacestat in adult desmoid tumours before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle le varegacestat dans les tumeurs desmoïdes de l'adulte avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-axs12",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve AXS-12 in cataplexy associated with narcolepsy before 31 May 2027?",
      "fr": "La FDA approuvera-t-elle l'AXS-12 dans la cataplexie associée à la narcolepsie avant le 31 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-encaleret",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve encaleret in autosomal dominant hypocalcemia type 1 before 15 June 2027?",
      "fr": "La FDA approuvera-t-elle l'encaleret dans l'hypocalcémie autosomique dominante de type 1 avant le 15 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-bezuclastinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bezuclastinib in advanced systemic mastocytosis before 31 July 2027?",
      "fr": "La FDA approuvera-t-elle le bezuclastinib dans la mastocytose systémique avancée avant le 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": "2026-10-05",
     "id": "med-vax31-opus2",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will Vaxcyte publish topline results from the phase 3 OPUS-2 trial before 31 July 2027?",
      "fr": "Vaxcyte publiera-t-elle les résultats principaux de l'essai de phase 3 OPUS-2 avant le 31 juillet 2027 ?"
     },
     "source": "SEC : 5 dépôt(s) 8-K contenant \"OPUS-2\" — le plus récent du 2026-10-05 (Vaxcyte, Inc.  (PCVX)  (CIK 0001649094))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1649094/000119312526413168/d21202dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-retatrutide-depot",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will the FDA accept the retatrutide NDA filing in obesity before 30 September 2027?",
      "fr": "La FDA acceptera-t-elle le dépôt de la NDA du rétatrutide dans l'obésité avant le 30 septembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": "2026-09-30",
     "id": "med-intismeran",
     "note": "indice trouvé, vérification humaine nécessaire",
     "par": "edgar",
     "question": {
      "en": "Will a regulator accept a registration filing for intismeran autogene combined with pembrolizumab in resected melanoma before 31 December 2027?",
      "fr": "Un régulateur acceptera-t-il un dossier d'enregistrement pour l'intismeran autogène associé au pembrolizumab dans le mélanome réséqué avant le 31 décembre 2027 ?"
     },
     "source": "SEC : 1 dépôt(s) 8-K contenant \"intismeran\" — le plus récent du 2026-09-30 (Moderna, Inc.  (MRNA)  (CIK 0001682852))",
     "statut": "à vérifier",
     "url": "https://www.sec.gov/Archives/edgar/data/1682852/000119312526408289/d18337dex991.htm",
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-bepirovirsen",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve bepirovirsen for chronic hepatitis B?",
      "fr": "La FDA approuvera-t-elle le bépirovirsen contre l'hépatite B chronique ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-neladalkib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve neladalkib (NVL-655) for ALK-positive non-small cell lung cancer?",
      "fr": "La FDA approuvera-t-elle le néladalkib (NVL-655) contre le cancer du poumon ALK-positif ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-imsidolimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve imsidolimab for generalized pustular psoriasis?",
      "fr": "La FDA approuvera-t-elle l’imsidolimab contre le psoriasis pustuleux généralisé ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-relacorilant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve relacorilant for hypercortisolism (Cushing's syndrome)?",
      "fr": "La FDA approuvera-t-elle le relacorilant contre l'hypercortisolisme (syndrome de Cushing) ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-lorundrostat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve lorundrostat for hypertension?",
      "fr": "La FDA approuvera-t-elle le lorundrostat contre l’hypertension ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fed-oct2026",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the October 27-28, 2026 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fed-20261209",
     "note": null,
     "par": "fed",
     "question": {
      "en": "Will the FOMC raise its federal funds rate target range at the 2026-12-09 meeting?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641076",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641076 (MoonLake Immunotherapeutics AG) still show a study completion date of 4 February 2027 or earlier when checked on 6 March 2027?",
      "fr": "L'essai NCT06641076 (MoonLake Immunotherapeutics AG) affichera-t-il encore une fin d'étude au 4 février 2027 ou avant, à la vérification du 6 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct04529772",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04529772 (Acerta Pharma BV) still show a study completion date of 22 February 2027 or earlier when checked on 24 March 2027?",
      "fr": "L'essai NCT04529772 (Acerta Pharma BV) affichera-t-il encore une fin d'étude au 22 février 2027 ou avant, à la vérification du 24 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05531656",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05531656 (Cognition Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT05531656 (Cognition Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct04906395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04906395 (Tolmar Inc.) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT04906395 (Tolmar Inc.) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct07000136",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07000136 (AstraZeneca) still show a study completion date of 4 January 2027 or earlier when checked on 3 February 2027?",
      "fr": "L'essai NCT07000136 (AstraZeneca) affichera-t-il encore une fin d'étude au 4 janvier 2027 ou avant, à la vérification du 3 février 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05438407",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05438407 (Pharming Technologies B.V.) still show a study completion date of 30 December 2026 or earlier when checked on 29 January 2027?",
      "fr": "L'essai NCT05438407 (Pharming Technologies B.V.) affichera-t-il encore une fin d'étude au 30 décembre 2026 ou avant, à la vérification du 29 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06260163",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06260163 (Janssen Research & Development, LLC) still show a study completion date of 28 April 2027 or earlier when checked on 28 May 2027?",
      "fr": "L'essai NCT06260163 (Janssen Research & Development, LLC) affichera-t-il encore une fin d'étude au 28 avril 2027 ou avant, à la vérification du 28 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct03319667",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03319667 (Sanofi) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT03319667 (Sanofi) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06736041",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06736041 (Sanofi Pasteur, a Sanofi Company) still show a study completion date of 17 May 2027 or earlier when checked on 16 June 2027?",
      "fr": "L'essai NCT06736041 (Sanofi Pasteur, a Sanofi Company) affichera-t-il encore une fin d'étude au 17 mai 2027 ou avant, à la vérification du 16 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05445778",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05445778 (AbbVie) still show a study completion date of 31 May 2032 or earlier when checked on 30 June 2032?",
      "fr": "L'essai NCT05445778 (AbbVie) affichera-t-il encore une fin d'étude au 31 mai 2032 ou avant, à la vérification du 30 juin 2032 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct03574571",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03574571 (Memorial Sloan Kettering Cancer Center) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT03574571 (Memorial Sloan Kettering Cancer Center) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05850689",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05850689 (Intra-Cellular Therapies, Inc.) still show a study completion date of 5 April 2027 or earlier when checked on 5 May 2027?",
      "fr": "L'essai NCT05850689 (Intra-Cellular Therapies, Inc.) affichera-t-il encore une fin d'étude au 5 avril 2027 ou avant, à la vérification du 5 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct03815643",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT03815643 (EMD Serono Research & Development Institute, Inc.) still show a study completion date of 24 November 2026 or earlier when checked on 24 December 2026?",
      "fr": "L'essai NCT03815643 (EMD Serono Research & Development Institute, Inc.) affichera-t-il encore une fin d'étude au 24 novembre 2026 ou avant, à la vérification du 24 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05063162",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05063162 (UCB Biopharma SRL) still show a study completion date of 1 July 2027 or earlier when checked on 31 July 2027?",
      "fr": "L'essai NCT05063162 (UCB Biopharma SRL) affichera-t-il encore une fin d'étude au 1 juillet 2027 ou avant, à la vérification du 31 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06506955",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06506955 (Taiho Oncology, Inc.) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06506955 (Taiho Oncology, Inc.) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct07102628",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07102628 (Novartis Pharmaceuticals) still show a study completion date of 11 February 2027 or earlier when checked on 13 March 2027?",
      "fr": "L'essai NCT07102628 (Novartis Pharmaceuticals) affichera-t-il encore une fin d'étude au 11 février 2027 ou avant, à la vérification du 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06489028",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06489028 (RHEACELL GmbH & Co. KG) still show a study completion date of 30 September 2027 or earlier when checked on 30 October 2027?",
      "fr": "L'essai NCT06489028 (RHEACELL GmbH & Co. KG) affichera-t-il encore une fin d'étude au 30 septembre 2027 ou avant, à la vérification du 30 octobre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06388200",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06388200 (Ocugen) still show a study completion date of 12 February 2027 or earlier when checked on 14 March 2027?",
      "fr": "L'essai NCT06388200 (Ocugen) affichera-t-il encore une fin d'étude au 12 février 2027 ou avant, à la vérification du 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct01953588",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT01953588 (Alliance for Clinical Trials in Oncology) still show a study completion date of 1 April 2027 or earlier when checked on 1 May 2027?",
      "fr": "L'essai NCT01953588 (Alliance for Clinical Trials in Oncology) affichera-t-il encore une fin d'étude au 1 avril 2027 ou avant, à la vérification du 1 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06641466",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06641466 (Pfizer) still show a study completion date of 30 March 2027 or earlier when checked on 29 April 2027?",
      "fr": "L'essai NCT06641466 (Pfizer) affichera-t-il encore une fin d'étude au 30 mars 2027 ou avant, à la vérification du 29 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05987956",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05987956 (Medicine Invention Design, Inc) still show a study completion date of 28 December 2026 or earlier when checked on 27 January 2027?",
      "fr": "L'essai NCT05987956 (Medicine Invention Design, Inc) affichera-t-il encore une fin d'étude au 28 décembre 2026 ou avant, à la vérification du 27 janvier 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct04031677",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) still show a study completion date of 21 April 2028 or earlier when checked on 21 May 2028?",
      "fr": "L'essai NCT04031677 (European Organisation for Research and Treatment of Cancer - EORTC) affichera-t-il encore une fin d'étude au 21 avril 2028 ou avant, à la vérification du 21 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct04462770",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04462770 (Epygenix) still show a study completion date of 31 May 2029 or earlier when checked on 30 June 2029?",
      "fr": "L'essai NCT04462770 (Epygenix) affichera-t-il encore une fin d'étude au 31 mai 2029 ou avant, à la vérification du 30 juin 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05696613",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05696613 (Cerium Pharmaceuticals, Inc.) still show a study completion date of 31 December 2027 or earlier when checked on 30 January 2028?",
      "fr": "L'essai NCT05696613 (Cerium Pharmaceuticals, Inc.) affichera-t-il encore une fin d'étude au 31 décembre 2027 ou avant, à la vérification du 30 janvier 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06498414",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) still show a study completion date of 1 June 2029 or earlier when checked on 1 July 2029?",
      "fr": "L'essai NCT06498414 (McGill University Health Centre/Research Institute of the McGill University Health Centre) affichera-t-il encore une fin d'étude au 1 juin 2029 ou avant, à la vérification du 1 juillet 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06733129",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06733129 (Nantes University Hospital) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06733129 (Nantes University Hospital) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06360133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06360133 (VivaVision Biotech, Inc) still show a study completion date of 30 April 2027 or earlier when checked on 30 May 2027?",
      "fr": "L'essai NCT06360133 (VivaVision Biotech, Inc) affichera-t-il encore une fin d'étude au 30 avril 2027 ou avant, à la vérification du 30 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06987695",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06987695 (Amgen) still show a study completion date of 21 July 2027 or earlier when checked on 20 August 2027?",
      "fr": "L'essai NCT06987695 (Amgen) affichera-t-il encore une fin d'étude au 21 juillet 2027 ou avant, à la vérification du 20 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06427395",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06427395 (Zydus Therapeutics Inc.) still show a study completion date of 18 July 2027 or earlier when checked on 17 August 2027?",
      "fr": "L'essai NCT06427395 (Zydus Therapeutics Inc.) affichera-t-il encore une fin d'étude au 18 juillet 2027 ou avant, à la vérification du 17 août 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06334133",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06334133 (vTv Therapeutics) still show a study completion date of 31 May 2027 or earlier when checked on 30 June 2027?",
      "fr": "L'essai NCT06334133 (vTv Therapeutics) affichera-t-il encore une fin d'étude au 31 mai 2027 ou avant, à la vérification du 30 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06998524",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06998524 (Hoffmann-La Roche) still show a study completion date of 30 April 2029 or earlier when checked on 30 May 2029?",
      "fr": "L'essai NCT06998524 (Hoffmann-La Roche) affichera-t-il encore une fin d'étude au 30 avril 2029 ou avant, à la vérification du 30 mai 2029 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06693895",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06693895 (GlaxoSmithKline) still show a study completion date of 23 November 2026 or earlier when checked on 23 December 2026?",
      "fr": "L'essai NCT06693895 (GlaxoSmithKline) affichera-t-il encore une fin d'étude au 23 novembre 2026 ou avant, à la vérification du 23 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06804811",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06804811 (Incyte Corporation) still show a study completion date of 1 December 2027 or earlier when checked on 31 December 2027?",
      "fr": "L'essai NCT06804811 (Incyte Corporation) affichera-t-il encore une fin d'étude au 1 décembre 2027 ou avant, à la vérification du 31 décembre 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct04057898",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT04057898 (MediciNova) still show a study completion date of 30 April 2028 or earlier when checked on 30 May 2028?",
      "fr": "L'essai NCT04057898 (MediciNova) affichera-t-il encore une fin d'étude au 30 avril 2028 ou avant, à la vérification du 30 mai 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct05667142",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT05667142 (Xenon Pharmaceuticals Inc.) still show a study completion date of 30 June 2027 or earlier when checked on 30 July 2027?",
      "fr": "L'essai NCT05667142 (Xenon Pharmaceuticals Inc.) affichera-t-il encore une fin d'étude au 30 juin 2027 ou avant, à la vérification du 30 juillet 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct07094087",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07094087 (CSL Behring) still show a study completion date of 5 May 2027 or earlier when checked on 4 June 2027?",
      "fr": "L'essai NCT07094087 (CSL Behring) affichera-t-il encore une fin d'étude au 5 mai 2027 ou avant, à la vérification du 4 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct06717711",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT06717711 (Regina Elena Cancer Institute) still show a study completion date of 28 February 2028 or earlier when checked on 29 March 2028?",
      "fr": "L'essai NCT06717711 (Regina Elena Cancer Institute) affichera-t-il encore une fin d'étude au 28 février 2028 ou avant, à la vérification du 29 mars 2028 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ma-diversified-energy-company-birch-permian-q1hzy",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Diversified Energy Company officially complete its acquisition of Birch Permian Holdings, Inc. and its affiliated entities on or before April 3, 2027?",
      "fr": "Diversified Energy Company finalisera-t-elle officiellement son acquisition de Birch Permian Holdings, Inc. et de ses entités affiliées au plus tard le 3 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-eci-1700-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Epoch Capabilities Index (ECI) score in Epoch AI's benchmark data reach at least 170.0 for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-nct07216079",
     "note": null,
     "par": "ctgov",
     "question": {
      "en": "Will NCT07216079 (Sanofi) still show a study completion date of 30 November 2026 or earlier when checked on 30 December 2026?",
      "fr": "L'essai NCT07216079 (Sanofi) affichera-t-il encore une fin d'étude au 30 novembre 2026 ou avant, à la vérification du 30 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202610-145",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.45 °C (vs. 1951–1980) for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "clim-seaice-202610-705",
     "note": null,
     "par": "banquise",
     "question": {
      "en": "Will the NSIDC Sea Ice Index report an average Northern Hemisphere sea ice extent of at least 7.05 million km² for October 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-hle-585-20261206",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Humanity's Last Exam (HLE) accuracy score in Epoch AI's benchmark data reach at least 58.5 % for a model released on or before 2026-12-06?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fin-unrate-202611-42",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. unemployment rate for November 2026 be at least 4.2 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202610-34",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for October 2026 be at least 3.4 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fin-dgs10-202611-545",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. 10-year Treasury yield at the close of the last business day of November 2026 be at least 5.45 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261017-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 17, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-deucrictibant",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Pharvaris's deucrictibant for on-demand treatment of hereditary angioedema attacks by May 7, 2027?",
      "fr": "La FDA approuvera-t-elle deucrictibant de Pharvaris (indication : traitement à la demande des crises d'angioedème héréditaire) d'ici le 7 mai 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-obexelimab",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Zenas BioPharma's obexelimab for treatment of Immunoglobulin G4-Related Disease by June 10, 2027?",
      "fr": "La FDA approuvera-t-elle obexelimab de Zenas BioPharma (indication : traitement de la maladie liée aux IgG4) d'ici le 10 juin 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-ozekibart",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inhibrx Biosciences's ozekibart for conventional chondrosarcoma by April 28, 2027?",
      "fr": "La FDA approuvera-t-elle ozekibart de Inhibrx Biosciences (indication : chondrosarcome conventionnel) d'ici le 28 avril 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "clim-gistemp-202611-140",
     "note": null,
     "par": "climat",
     "question": {
      "en": "Will NASA GISS report a global surface temperature anomaly of at least +1.40 °C (vs. 1951–1980) for November 2026?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-zipalertinib",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Cullinan Therapeutics's zipalertinib for Locally advanced or metastatic EGFR exon 20 insertion NSCLC after platinum chemotherapy by March 13, 2027?",
      "fr": "La FDA approuvera-t-elle zipalertinib de Cullinan Therapeutics (indication : NSCLC avancé localement ou métastatique avec insertion exon 20 EGFR après chimiothérapie au platine) d'ici le 13 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-descartes-08-aurora-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Cartesian Therapeutics announce topline results from the AURORA trial of Descartes-08 in generalized Myasthenia Gravis by March 31, 2027?",
      "fr": "Cartesian Therapeutics annoncera-t-elle les résultats principaux de l'essai AURORA de Descartes-08 (indication : myasthénie généralisée) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-duravyu-lucia-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will EyePoint announce topline results from the LUCIA trial of DURAVYU in wet age-related macular degeneration by December 31, 2026?",
      "fr": "EyePoint annoncera-t-elle les résultats principaux de l'essai LUCIA de DURAVYU (indication : dégénérescence maculaire liée à l'âge humide) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-pmn310-precise-ad-202703",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ProMIS Neurosciences announce topline results from the PRECISE-AD trial of PMN310 in early Alzheimer’s disease by March 31, 2027?",
      "fr": "ProMIS Neurosciences annoncera-t-elle les résultats principaux de l'essai PRECISE-AD de PMN310 (indication : maladie d'Alzheimer précoce) d'ici le 31 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-bmf-650-glp-131-202610",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biomea Fusion announce topline results from the GLP-131 trial of BMF-650 in obesity in otherwise healthy volunteers by October 31, 2026?",
      "fr": "Biomea Fusion annoncera-t-elle les résultats principaux de l'essai GLP-131 de BMF-650 (indication : obésité chez des volontaires autrement sains) d'ici le 31 octobre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-ino-3107",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Inovio Pharmaceuticals's INO-3107 for Recurrent Respiratory Papillomatosis by November 13, 2026?",
      "fr": "La FDA approuvera-t-elle INO-3107 de Inovio Pharmaceuticals (indication : Papillomatose respiratoire récurrente) d'ici le 13 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-mitapivat",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Agios's mitapivat for sickle cell disease by November 15, 2026?",
      "fr": "La FDA approuvera-t-elle mitapivat de Agios (indication : drépanocytose) d'ici le 15 novembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-firmonertinib-furvent-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will ArriVent BioPharma announce topline results from the FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC by December 31, 2026?",
      "fr": "ArriVent BioPharma annoncera-t-elle les résultats principaux de l'essai FURVENT de firmonertinib (indication : NSCLC à mutation d'exon 20 d'EGFR en première ligne) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-opakalim-rise3-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Biohaven announce topline results from the RISE3 trial of opakalim in focal epilepsy by December 31, 2026?",
      "fr": "Biohaven annoncera-t-elle les résultats principaux de l'essai RISE3 de opakalim (indication : épilepsie focale) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "rd-selinexor-xport-mm-031-202612",
     "note": null,
     "par": "edgar",
     "question": {
      "en": "Will Karyopharm Therapeutics announce topline results from the XPORT-MM-031 trial of selinexor in previously treated multiple myeloma by December 31, 2026?",
      "fr": "Karyopharm Therapeutics annoncera-t-elle les résultats principaux de l'essai XPORT-MM-031 de selinexor (indication : myélome multiple précédemment traité) d'ici le 31 décembre 2026 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-ad109",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Apnimed's AD109 (Oxnimbi) for treatment of adults with obstructive sleep apnea by March 14, 2027?",
      "fr": "La FDA approuvera-t-elle AD109 (Oxnimbi) de Apnimed (indication : traitement des adultes atteints d'apnée obstructive du sommeil) d'ici le 14 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-chess-820-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest Chess Puzzles score score in Epoch AI's benchmark data reach at least 82.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-scicode-705-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SciCode score score in Epoch AI's benchmark data reach at least 70.5 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "ia-epoch-simpleqa-830-20261213",
     "note": null,
     "par": "epoch",
     "question": {
      "en": "Will the highest SimpleQA Verified score score in Epoch AI's benchmark data reach at least 83.0 % for a model released on or before 2026-12-13?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "med-dibutepinephrine",
     "note": null,
     "par": "openfda",
     "question": {
      "en": "Will the FDA approve Aquestive Therapeutics's dibutepinephrine (Anaphylm) for treatment of Type I allergic reactions, including anaphylaxis by March 30, 2027?",
      "fr": "La FDA approuvera-t-elle dibutepinephrine (Anaphylm) de Aquestive Therapeutics (indication : traitement des réactions allergiques de type I, y compris l’anaphylaxie) d'ici le 30 mars 2027 ?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "fin-cpi-202611-37",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will the U.S. annual CPI inflation rate for November 2026 be at least 3.7 %?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    },
    {
     "date_evenement": null,
     "id": "emp-icsa-20261024-205",
     "note": null,
     "par": "macro",
     "question": {
      "en": "Will U.S. initial jobless claims (seasonally adjusted) for the week ending Saturday October 24, 2026 be at least 205,000?"
     },
     "source": null,
     "statut": "ouvert",
     "url": null,
     "valide": false,
     "verdict": null,
     "vu_le": "2026-10-18"
    }
   ],
   "le": "2026-10-18T06:30:27.617Z"
  }
 ]
}